A Texas judge has finalized a $158 million settlement between Texas and a subsidiary of health care giant Johnson & Johnson in a Medicaid fraud lawsuit over the anti-psychotic drug Risperdal.
The agreement, reached during a January trial settled a lawsuit that accused J&J and its subsidiaries of fraud by false or misleading statements about the safety, cost and effectiveness of the drug.
The settlement was approved during a court hearing Tuesday in Austin.
The whistleblower lawsuit was filed by Allen Jones. His attorney, Tom Melsheimer, said Texas will get 40 percent of the settlement; the federal government gets 31 percent; Jones gets 17 percent; and 12 percent goes to attorneys’ fees.
The health care giant has said it’s not admitting fault with the settlement.
Topics Lawsuits Texas Legislation
Was this article valuable?
Here are more articles you may enjoy.
Hedge Funds Are Expanding Desks Designed to Profit From Natural-Catastrophe Risk 
AI Savings Misses ‘Should Be Making Executives Uncomfortable,’ Bain Says 
Helicopter Crash in Georgia Kills Groom, Pilot, Hours After Huge Wedding Celebration 
Natural-Disaster Insurance Gap Now Exceeds $420 Billion Globally 
